How do you incorporate MRD into treatment decision-making in clinical practice?

During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?

Van Besien begins by discussing the complexities around the two major technologies we use to detect MRD, flow cytometry and molecular testing. He outlines reliable MRD tests, settings in which they can be used, and treatment options, such as MRD testing during induction for MPN1 mutated AML. He also describes the necessity for allogenic transplant consolidation in MRD- patients. Finally, he highlights the increasing data on maintenance therapy for patients that remain MRD+ e.g. TKI inhibitors.